Diabetic Foot Ulcer Clinical Trials Findings

Diabetes resulted in delayed wound healing due to impairment in the inflammation and angiogenesis mechanism. Diabetic ulcer most commonly happened in the foot, which is a leading cause to lower extremity amputation. MSCs is known to regulate inflammation and angiogenesis via secretion of various growth factors and cytokines that were involved in both mechanisms. DCGI has approved the phase 3 clinical trial for diabetic foot ulcer whereby 84 patients were divided equally to receive Stempeucel^® and placebo. Study was done across India consisting of 17 hospitals. Stempeucel^® injection in and around the wound bed, demonstrates accentuation of the healing process and reduction of the ulcer area.